It is somewhat confusing to me as the graph on the

Quote:

---

It is somewhat confusing to me as the graph on the left has 2 red symbols meaning “Progression with new disease”. Can progression be considered stable, depending on the degree of progression? One of those two continued Leronlimab and could have responded later.

---

Progression means more than 20% tumor growth. Partial response is more than 30% reduction in tumor size. Anything in-between is considered stable disease.

Patient 901-021 is the one who dropped out of the study.

Patient 901-030 was the patient who had no measurable lesion on PET. The progression shown must have used some other measurement.

Patient 901-034 initially responded to treatment but then tumor size rebounded. There may have been a change a change of treatment other than leronlimab (for example on ICIs then taken off). The red square would mean progression with new disease. It looks like the patient stopped treatment at that time but there may be further data available.

Patient 901-023 seemed to leave the trial prematurely although showing improvement.

Patients 901-019 and 901-058 showed very good improvement but no further PET scans after around 3 months and 6 months.

Follow-up on the trial was up to two years. But Cytodyn may have acquired new data that extends past that date when it comes to survival. Cytodyn probably would not be presenting at ESMO just based on the data shown there. They may have better data on at least two patients and may have additional data from compassionate use.